Scarica l'app Stockscreener
34.26
0.03%
-0.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$34.27
Aprire:
$34.03
Volume 24 ore:
2.84M
Relative Volume:
0.56
Capitalizzazione di mercato:
$3.87B
Reddito:
-
Utile/perdita netta:
$-99.15M
Rapporto P/E:
-36.84
EPS:
-0.93
Flusso di cassa netto:
$-74.25M
1 W Prestazione:
-12.40%
1M Prestazione:
+3.88%
6M Prestazione:
+25.72%
1 anno Prestazione:
-33.64%
Intervallo 1D:
$32.90
$34.93
Intervallo di 1 settimana:
$32.90
$38.75
Portata 52W:
$18.92
$56.25
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Confronta VKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
34.26 | 3.87B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-29 | Iniziato | Canaccord Genuity | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics Stock: A Turning Point Emerges - Ad-hoc-news.de
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon - The Motley Fool
Viking Therapeutics Stock: A Transformative Week for the Biotech Firm - Ad-hoc-news.de
What drives Viking Therapeutics Inc stock priceStock Price Divergence & Low Cost Portfolio Tips - earlytimes.in
Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue? - sharewise.com
Will Viking Therapeutics Inc. (1VT) stock deliver compounding returnsOil Prices & Fast Exit/Entry Strategy Plans - newser.com
Viking Therapeutics concludes enrolment in Phase III trial of obesity therapy - Clinical Trials Arena
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential - Finviz
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug - Yahoo Finance
How (VKTX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Viking Therapeutics stock holds Buy rating as obesity trial enrollment completes - Investing.com India
Is Viking Therapeutics Inc. stock a top momentum playBull Run & Technical Pattern Recognition Alerts - newser.com
Using Bollinger Bands to evaluate Viking Therapeutics Inc.Product Launch & Reliable Entry Point Alerts - newser.com
Can Viking Therapeutics Inc. (1VT) stock sustain margin levelsWeekly Trade Review & Capital Protection Trading Alerts - newser.com
Viking Therapeutics, Up 62% Since August, Undercuts A Buy Zone Despite Key Win - Investor's Business Daily
Can Viking Therapeutics Inc. stock reach $100 price target2025 Top Decliners & Daily Profit Focused Stock Screening - newser.com
Viking therapeutics completes enrollment in obesity drug trial By Investing.com - Investing.com Nigeria
William Blair Reiterates “Buy” Rating on Viking Therapeutics (VKTX) Following New VK2735 Data - MSN
Why Viking Therapeutics Inc. (1VT) stock attracts HNW investorsJuly 2025 Decliners & Fast Exit and Entry Strategy Plans - newser.com
Why Viking Therapeutics Inc. stock could see breakout soonJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
How to Invest in Viking Therapeutics (VKTX) - The Motley Fool
Viking Therapeutics : November 2025 Corporate Presentation - MarketScreener
Strong Enrollment and Promising Strategy Propel Viking Therapeutics to ‘Buy’ Rating - TipRanks
Viking Therapeutics (VKTX) Stock: Investors Eye 78-Week Readout After Ahead-of-Schedule Phase 3 Progress - parameter.io
Viking Therapeutics, Up 62% Since August, Lingers In Buy Zone On An Obesity Win - MSN
Viking: Playfield Has Changed, Downgrading To Hold After A Strong Run (NASDAQ:VKTX) - Seeking Alpha
Promising Potential of Viking Therapeutics’ VK2735 Justifies Buy Rating - TipRanks
Is Viking Therapeutics Inc. stock a buy before product launchesInflation Watch & Technical Pattern Based Buy Signals - newser.com
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. - AOL.com
Viking Therapeutics (VKTX) Completes Enrollment for Key Phase 3 Trial - GuruFocus
What consensus target says about Viking Therapeutics Inc. (1VT) stockOil Prices & Capital Protection Trade Alerts - newser.com
Why Viking Therapeutics Inc. stock is popular among millennialsMarket Trend Summary & Verified Swing Trading Watchlists - newser.com
Viking Therapeutics at Jefferies: Strategic Insights on Obesity Drug By Investing.com - Investing.com India
Viking Therapeutics at Jefferies: Strategic Insights on Obesity Drug - Investing.com
Viking Therapeutics Completes Enrollment in Phase 3 Vanquish 1 Obesity Trial - MarketScreener
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 - Finviz
Viking therapeutics completes enrollment in obesity drug trial - Investing.com India
Stocks To Watch: Viking Therapeutics Sees Relative Strength Rating Rise To 89 - Investor's Business Daily
Signal strength of Viking Therapeutics Inc. stock in tech scannersChart Signals & Capital Protection Trade Alerts - newser.com
What makes Viking Therapeutics Inc. stock attractive to growth fundsJuly 2025 Reactions & Intraday High Probability Setup Alerts - newser.com
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):